Several clinical trials have performed subgroup analyses based on PD-L1 CPS cutoff values of 1, 5, and 10 in treatment-naive advanced G/GEJ adenocarcinomas; nevertheless, inconsistent outcomes were observed [21, 23]. This evidence concerns the gene CD274 and gastroesophageal junction adenocarcinoma.